Prognostic value of the D-dimer test in oesophageal cancer during the perioperative period

Journal of Surgical Oncology

Volumn 108, Issue 1, 2013, Pages 34-41

  Diao, Dongmei ^a   Zhu, Kun ^a   Wang, Zhe ^b   Cheng, Yao ^a   Li, Kang ^a   Pei, Leilei ^c   Dang, Chengxue ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^c MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

D dimer; oesophageal cancer; surgery; survival

Indexed keywords

D DIMER;

ADULT; ARTICLE; BENIGN TUMOR; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROL GROUP; ESOPHAGUS CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGE FACTORS; AGED; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PERIOPERATIVE PERIOD; PROGNOSIS; RADIOTHERAPY, ADJUVANT;

EID: 84879414752     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23339     Document Type: Article

References (45)

1. Green KB, Silverstein RL:, Hypercoagulability in cancer. Hematol Oncol Clin North Am 1996; 10: 499-530.
2. Abramson N, Aster RH:, Retrospective assessment of hypercoagulability in breast cancer prevention trial. J Clin Oncol 2002; 20: 4133-4134.
3. Lip GY, Chin BS, Blann AD:, Cancer and the prothrombotic state. Lancet Oncol 2002; 3: 27-34.
4. Noble S, Pasi J:, Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010; 102: S2-S9.
5. Paneesha S, McManus A, Arya R, et al.: Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics. Thromb Haemost 2010; 103: 338-343.
6. Ay C, Dunkler D, Simanek R, et al.: Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: Results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011; 29: 2099-2103.
7. Sorensen HT, Svaerke C, Farkas DK, et al.: Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer. Eur J Cancer 2012; 48: 586-593.
8. Franchini M, Montagnana M, Favaloro EJ, et al.: The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread. Semin Thromb Hemost 2009; 35: 644-653.
9. Wang JG, Geddings JE, Aleman MM, et al.: Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 2012; 119: 5543-5552.
10. Olas B, Wachowicz B, Mielicki WP:, Cancer procoagulant and blood platelet activation. Cancer Lett 2001; 169: 165-171.
11. Kamocka M, Rozalski M, Krajewska U, et al.: Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro. Cancer Lett 2005; 222: 89-94.
12. Kasthuri RS, Taubman MB, Mackman N:, Role of tissue factor in cancer. J Clin Oncol 2009; 27: 4834-4838.
13. Van den Berg YW, Osanto S, Reitsma PH, et al.: The relationship between tissue factor and cancer progression: Insights from bench and bedside. Blood 2012; 119: 924-932.
14. Gouin-Thibault I, Samama MM:, Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost 1999; 25: 167-172.
15. Kwaan HC, Bongu A:, The hyperviscosity syndromes. Semin Thromb Hemost 1999; 25: 199-208.
16. Klerk CP, Smorenburg SM, Spek CA, et al.: Colon cancer metastasis in mouse liver is not affected by hypercoagulability due to Factor V Leiden mutation. J Cell Mol Med 2007; 11: 561-568.
17. Vormittag R, Simanek R, Ay C, et al.: High factor VIII levels independently predict venous thromboembolism in cancer patients: The cancer and thrombosis study. Arterioscler Thromb Vasc Biol 2009; 29: 2176-2181.
18. Ruf W, Disse J, Carneiro-Lobo TC, et al.: Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost 2011; 9: 306-315.
19. Dupuy E, Hainaud P, Villemain A, et al.: Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in a transgenic mouse model. J Hepatol 2003; 38: 793-802.
20. Schaffner F, Versteeg HH, Schillert A, et al.: Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood 2010; 116: 6106-6113.
21. Buller HR, van DFF vanSGL, et al.: Cancer and thrombosis: From molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5: 246-254.
22. Boccaccio C, Comoglio PM:, Genetic link between cancer and thrombosis. J Clin Oncol 2009; 27: 4827-4833.
23. Lippi G, Franchini M, Biasiutti C, et al.: Increased D-dimer value and occult cancer in the absence of detectable thrombosis. Haematologica 2007; 92: e53-e55.
24. Righini M, Perrier A, De Moerloose P, et al.: D-Dimer for venous thromboembolism diagnosis: 20 Years later. J Thromb Haemost 2008; 6: 1059-1071.
25. Ay C, Vormittag R, Dunkler D, et al.: D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27: 4124-4129.
26. Edwards CM, Warren J, Armstrong L, et al.: D-dimer: A useful marker of disease stage in surgery for colorectal cancer. Br J Surg 1993; 80: 1404-1405.
27. Taguchi O, Gabazza EC, Yasui H, et al.: Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax 1997; 52: 563-565.
28. Blackwell K, Haroon Z, Broadwater G, et al.: Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000; 18: 600-608.
29. Dirix LY, Salgado R, Weytjens R, et al.: Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-395.
30. Batschauer AP, Figueiredo CP, Bueno EC, et al.: D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol 2010; 21: 1267-1272.
31. Ay C, Dunkler D, Pirker R, et al.: High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012; 97: 1158-1164.
32. Franchini M, Montagnana M, Targher G, et al.: Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 2007; 24: 29-38.
33. Stender MT, Frokjaer JB, Hagedorn NTS, et al.: Combined use of clinical pre-test probability and D-dimer test in the diagnosis of preoperative deep venous thrombosis in colorectal cancer patients. Thromb Haemost 2008; 99: 396-400.
34. Behranwala KA, Williamson RC:, Cancer-associated venous thrombosis in the surgical setting. Ann Surg 2009; 249: 366-375.
35. Byrne M, Reynolds JV, O'Donnell JS, et al.: Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery. Br J Cancer 2010; 102: 73-79.
36. Blackwell K, Hurwitz H, Lieberman G, et al.: Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004; 101: 77-82.
37. Guadagni F, Ferroni P, Basili S, et al.: Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients. Lung Cancer 2004; 44: 303-310.
38. Antoniou D, Pavlakou G, Stathopoulos GP, et al.: Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer 2006; 53: 205-210.
39. Tomimaru Y, Yano M, Takachi K, et al.: Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J Am Coll Surg 2006; 202: 139-145.
40. Douma RA, Tan M, Schutgens R, et al.: Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded. Haematologica 2012; 97: 1505-1513.
41. Schaffner F, Ruf W:, Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 2008; 34: 147-153.
42. Lemoine NR:, Antithrombotic therapy in cancer. J Clin Oncol 2005; 23: 2119-2120.
43. Petralia GA, Lemoine NR, Kakkar AK:, Mechanisms of disease: The impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2005; 2: 356-363.
44. Cunningham MS, Preston RJ, O'Donnell JS:, Does antithrombotic therapy improve survival in cancer patients. Blood Rev 2009; 23: 129-135.
45. Di NM, Klerk CP, Meijers JC, et al.: The prognostic value of the D-dimer test in cancer patients treated with and without low-molecular-weight heparin. J Thromb Haemost 2005; 3: 1531-1533.